U.S., Oct. 1 -- ClinicalTrials.gov registry received information related to the study (NCT07850765) titled 'Real-World Patient and Physician Experience With Semaglutide Across Six Emerging Markets' on Sept. 23.
Brief Summary: The purpose of this study is to assess semaglutide's impact on daily life from participants and physicians experience.
Study Start Date: Aug. 28
Study Type: OBSERVATIONAL
Condition:
Overweight
Obesity
Intervention:
DRUG: Semaglutide
This is a retrospective, non-interventional study; therefore, no intervention was administered as part of the study.
Recruitment Status: COMPLETED
Sponsor: Novo Nordisk A/S
Published by HT Digital Content Services with permission from Health Daily Digest....